CN103080106A - 用作激酶抑制剂的环醚化合物 - Google Patents
用作激酶抑制剂的环醚化合物 Download PDFInfo
- Publication number
- CN103080106A CN103080106A CN2011800335423A CN201180033542A CN103080106A CN 103080106 A CN103080106 A CN 103080106A CN 2011800335423 A CN2011800335423 A CN 2011800335423A CN 201180033542 A CN201180033542 A CN 201180033542A CN 103080106 A CN103080106 A CN 103080106A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- amino
- equiv
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(C(NC(*)=O)=*)=**=* Chemical compound *C(C(NC(*)=O)=*)=**=* 0.000 description 16
- LFKDJXLFVYVEFG-UHFFFAOYSA-N CC(C)(C)OC(N)=O Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- ONVIACLNWQFOBK-UHFFFAOYSA-N CC(C)(C)[N](C)(C)C Chemical compound CC(C)(C)[N](C)(C)C ONVIACLNWQFOBK-UHFFFAOYSA-N 0.000 description 1
- OVQBFHCEJVOYQI-XBBDIZMDSA-N CC(C)(C)[SiH](C)O[C@@H](C[C@H](c(ccnc1)c1[N+]([O-])=O)OC1(C)C)[C@@H]1O Chemical compound CC(C)(C)[SiH](C)O[C@@H](C[C@H](c(ccnc1)c1[N+]([O-])=O)OC1(C)C)[C@@H]1O OVQBFHCEJVOYQI-XBBDIZMDSA-N 0.000 description 1
- BMWPFULBEJVQQV-FKYLOJIBSA-N CC(C)NC(c(cc1)cc(/C(/N=C(\C)/C(O)=O)=C(/C=C)\F)c1F)=O Chemical compound CC(C)NC(c(cc1)cc(/C(/N=C(\C)/C(O)=O)=C(/C=C)\F)c1F)=O BMWPFULBEJVQQV-FKYLOJIBSA-N 0.000 description 1
- OPTPSSHEDGAJPW-LVQVYYBASA-N CC(C)[C@H]([C@H]([C@@H](C1)NC(OC(C)(C)C)=O)O)O[C@H]1c(ccnc1)c1N Chemical compound CC(C)[C@H]([C@H]([C@@H](C1)NC(OC(C)(C)C)=O)O)O[C@H]1c(ccnc1)c1N OPTPSSHEDGAJPW-LVQVYYBASA-N 0.000 description 1
- WIOOTLXLCLDKHK-UHFFFAOYSA-N CC(CC(F)=C1C2NC(C(O)=O)=CC=C2F)C=C1F Chemical compound CC(CC(F)=C1C2NC(C(O)=O)=CC=C2F)C=C1F WIOOTLXLCLDKHK-UHFFFAOYSA-N 0.000 description 1
- FQNFACTVEIYKRG-BLLLJJGKSA-N CC(O[C@@H](CC1)C[C@H](c(ccnc2)c2[N+]([O-])=O)OC(C2CC2)=C1O)=O Chemical compound CC(O[C@@H](CC1)C[C@H](c(ccnc2)c2[N+]([O-])=O)OC(C2CC2)=C1O)=O FQNFACTVEIYKRG-BLLLJJGKSA-N 0.000 description 1
- QYLSMOGZIFJERJ-UPJWGTAASA-N CC(O[C@@H]1C=C(c(ccnc2)c2[N+]([O-])=O)O[C@H](CO)[C@H]1O)=O Chemical compound CC(O[C@@H]1C=C(c(ccnc2)c2[N+]([O-])=O)O[C@H](CO)[C@H]1O)=O QYLSMOGZIFJERJ-UPJWGTAASA-N 0.000 description 1
- JFFOTTSQJLRENT-UHFFFAOYSA-N CC1(C)OB(c(c(F)c(cc2)C(N(C)C)=O)c2F)OC1(C)C Chemical compound CC1(C)OB(c(c(F)c(cc2)C(N(C)C)=O)c2F)OC1(C)C JFFOTTSQJLRENT-UHFFFAOYSA-N 0.000 description 1
- IQFXJRXOTKFGPN-UHFFFAOYSA-N CCN(CC)C=C Chemical compound CCN(CC)C=C IQFXJRXOTKFGPN-UHFFFAOYSA-N 0.000 description 1
- MBBOTGYURVQWIF-UHFFFAOYSA-N CCOC(C1=CNC=C(c2ccccc2)C1=O)=O Chemical compound CCOC(C1=CNC=C(c2ccccc2)C1=O)=O MBBOTGYURVQWIF-UHFFFAOYSA-N 0.000 description 1
- BETFDCJHMAIVBA-FGRDXJNISA-N CC[C@@H](C(C)(C)[C@H](C1)OC(C)=O)OC1c(ccnc1)c1N Chemical compound CC[C@@H](C(C)(C)[C@H](C1)OC(C)=O)OC1c(ccnc1)c1N BETFDCJHMAIVBA-FGRDXJNISA-N 0.000 description 1
- JXIIMQNBQLSHOU-UPJWGTAASA-N CC[C@H]([C@H](C(C1)=O)O)O[C@H]1c1cc[n+](C)cc1[N+]([O-])=O Chemical compound CC[C@H]([C@H](C(C1)=O)O)O[C@H]1c1cc[n+](C)cc1[N+]([O-])=O JXIIMQNBQLSHOU-UPJWGTAASA-N 0.000 description 1
- UGHMFWGLAWDMBT-UHFFFAOYSA-N COC(c(cc(c(F)c1)Br)c1N)=[O]=C Chemical compound COC(c(cc(c(F)c1)Br)c1N)=[O]=C UGHMFWGLAWDMBT-UHFFFAOYSA-N 0.000 description 1
- LJCMMKJELAPZOV-NURSFMCSSA-N C[C@@H]1C[C@H](c(ccnc2)c2N)O[C@H](COC(C)=O)C1 Chemical compound C[C@@H]1C[C@H](c(ccnc2)c2N)O[C@H](COC(C)=O)C1 LJCMMKJELAPZOV-NURSFMCSSA-N 0.000 description 1
- GIQDCNUEJAQFKV-ZYOFANERSA-N C[C@H](C[C@H](c(ccnc1)c1N)O[C@@H]1C)[C@]1(CCCNCc1ccccc1)O Chemical compound C[C@H](C[C@H](c(ccnc1)c1N)O[C@@H]1C)[C@]1(CCCNCc1ccccc1)O GIQDCNUEJAQFKV-ZYOFANERSA-N 0.000 description 1
- SUVSELFSHADBRK-DNSOKLHBSA-N C[C@H]([C@@H](C)O[C@H](C1)c(ccnc2)c2[N+]([O-])=O)C1=O Chemical compound C[C@H]([C@@H](C)O[C@H](C1)c(ccnc2)c2[N+]([O-])=O)C1=O SUVSELFSHADBRK-DNSOKLHBSA-N 0.000 description 1
- KKSJFQHGMKIASG-JGMGGLLFSA-N C[C@H]([C@H](C)[C@H](c(ccnc1)c1N)O[C@@H]1C)[C@@H]1O Chemical compound C[C@H]([C@H](C)[C@H](c(ccnc1)c1N)O[C@@H]1C)[C@@H]1O KKSJFQHGMKIASG-JGMGGLLFSA-N 0.000 description 1
- UPHGJVUWCRGOKV-KDYMROGCSA-N C[C@H]([C@](C)([C@@H](C1)NC(OC(C)(C)C)=O)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)cc(C(N(C)C)=O)c2)c2F)c1F)=O Chemical compound C[C@H]([C@](C)([C@@H](C1)NC(OC(C)(C)C)=O)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)cc(C(N(C)C)=O)c2)c2F)c1F)=O UPHGJVUWCRGOKV-KDYMROGCSA-N 0.000 description 1
- RLCXIBVIZKXIJT-PTERYMMESA-N C[C@H]([C@](C)([C@@H]([C@H]1F)O[Si](C)(C)C(C)(C)C)O)O[C@H]1c(ccnc1)c1N Chemical compound C[C@H]([C@](C)([C@@H]([C@H]1F)O[Si](C)(C)C(C)(C)C)O)O[C@H]1c(ccnc1)c1N RLCXIBVIZKXIJT-PTERYMMESA-N 0.000 description 1
- HIAKCJKIVLUYBM-CQSZACIVSA-N C[Si+](C)(C)OC(C1)=CC2(CC2)O[C@H]1c(ccnc1)c1[N+]([O-])=O Chemical compound C[Si+](C)(C)OC(C1)=CC2(CC2)O[C@H]1c(ccnc1)c1[N+]([O-])=O HIAKCJKIVLUYBM-CQSZACIVSA-N 0.000 description 1
- MRPYPHHGUGOGSY-BHDDXSALSA-N N#CC[C@H]([C@H](CC1)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)ccc2)c2F)c1C#N)=O Chemical compound N#CC[C@H]([C@H](CC1)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)ccc2)c2F)c1C#N)=O MRPYPHHGUGOGSY-BHDDXSALSA-N 0.000 description 1
- LBASYCNGLJOSSX-PWRODBHTSA-N N#CC[C@H]([C@H](CC1)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)ccc2)c2F)c1F)=O Chemical compound N#CC[C@H]([C@H](CC1)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)ccc2)c2F)c1F)=O LBASYCNGLJOSSX-PWRODBHTSA-N 0.000 description 1
- PUKAYQCYGUDRAY-UHFFFAOYSA-N Nc1c(C2OCCCO2)ccnc1 Chemical compound Nc1c(C2OCCCO2)ccnc1 PUKAYQCYGUDRAY-UHFFFAOYSA-N 0.000 description 1
- JAOQUSFIYPHIMC-XCBNKYQSSA-N Nc1c([C@H](CC2)OC[C@@H]2O)ccnc1 Chemical compound Nc1c([C@H](CC2)OC[C@@H]2O)ccnc1 JAOQUSFIYPHIMC-XCBNKYQSSA-N 0.000 description 1
- FPAYBPUGCOPLJM-UHFFFAOYSA-N Nc1ccc(C2=NCCS2)nc1C(O)=O Chemical compound Nc1ccc(C2=NCCS2)nc1C(O)=O FPAYBPUGCOPLJM-UHFFFAOYSA-N 0.000 description 1
- WCRMEZPWARIASK-UHFFFAOYSA-N Nc1cnc(-c(cccc2)c2F)nc1C(O)O Chemical compound Nc1cnc(-c(cccc2)c2F)nc1C(O)O WCRMEZPWARIASK-UHFFFAOYSA-N 0.000 description 1
- AXXUKMYAQJKPMI-UHFFFAOYSA-N Nc1ncc(-c2ccccc2)nc1C(O)=O Chemical compound Nc1ncc(-c2ccccc2)nc1C(O)=O AXXUKMYAQJKPMI-UHFFFAOYSA-N 0.000 description 1
- GOHIYTWEZLRECD-UHFFFAOYSA-N [O-][N+](c(cncc1)c1C(C(F)(F)F)=O)=O Chemical compound [O-][N+](c(cncc1)c1C(C(F)(F)F)=O)=O GOHIYTWEZLRECD-UHFFFAOYSA-N 0.000 description 1
- CYMVNIANTHCYSU-UHFFFAOYSA-N [O-][N+](c1c(C(C2)(C(F)(F)F)OC=CC2=O)ccnc1)=O Chemical compound [O-][N+](c1c(C(C2)(C(F)(F)F)OC=CC2=O)ccnc1)=O CYMVNIANTHCYSU-UHFFFAOYSA-N 0.000 description 1
- QJUWWYDQJRXUDO-LDYMZIIASA-N [O-][N+](c1c([C@@H](C2)OC3(CC3)C[C@@H]2O)ccnc1)=O Chemical compound [O-][N+](c1c([C@@H](C2)OC3(CC3)C[C@@H]2O)ccnc1)=O QJUWWYDQJRXUDO-LDYMZIIASA-N 0.000 description 1
- DVXFDLWDPGTTSL-CYBMUJFWSA-N [O-][N+](c1c([C@@H](C2)OCCCCCC2=O)ccnc1)=O Chemical compound [O-][N+](c1c([C@@H](C2)OCCCCCC2=O)ccnc1)=O DVXFDLWDPGTTSL-CYBMUJFWSA-N 0.000 description 1
- UDQMAEUWUGSYAO-OASPWFOLSA-N [O-][N+](c1c([C@@H](C2)O[C@H](CCC3)[C@H]3C2=O)ccnc1)=O Chemical compound [O-][N+](c1c([C@@H](C2)O[C@H](CCC3)[C@H]3C2=O)ccnc1)=O UDQMAEUWUGSYAO-OASPWFOLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36175510P | 2010-07-06 | 2010-07-06 | |
| US61/361,755 | 2010-07-06 | ||
| PCT/EP2011/061198 WO2012004217A1 (en) | 2010-07-06 | 2011-07-04 | Cyclic ether compounds useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103080106A true CN103080106A (zh) | 2013-05-01 |
Family
ID=44279730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800335423A Pending CN103080106A (zh) | 2010-07-06 | 2011-07-04 | 用作激酶抑制剂的环醚化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130109682A1 (enExample) |
| EP (1) | EP2590968A1 (enExample) |
| JP (1) | JP2013530199A (enExample) |
| CN (1) | CN103080106A (enExample) |
| WO (1) | WO2012004217A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795151A (zh) * | 2014-08-06 | 2017-05-31 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| CN110713476A (zh) * | 2019-11-07 | 2020-01-21 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-甲基-4h-吡喃-4-酮的合成方法 |
| CN110790737A (zh) * | 2019-11-07 | 2020-02-14 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113501C2 (xx) | 2010-11-03 | 2017-02-10 | Пестицидні композиції і пов'язані з ними способи | |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| UY33930A (es) * | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
| CA2852688C (en) | 2011-10-26 | 2021-06-29 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| HK1209590A1 (en) | 2012-04-27 | 2016-04-08 | 陶氏益农公司 | Pesticidal compositions and processes related thereto |
| US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| WO2013175388A1 (en) | 2012-05-21 | 2013-11-28 | Novartis Ag | Novel ring-substituted n-pyridinyl amides as kinase inhibitors |
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| WO2014033630A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | Novel aminothiazole carboxamides as kinase inhibitors |
| WO2014033631A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | N-(3-pyridyl) biarylamides as kinase inhibitors |
| SI2900657T1 (sl) * | 2012-09-26 | 2020-07-31 | F. Hoffmann-La Roche Ag | Ciklični eter pirazol-4-il-heterociklil-karboksamidne spojine in načini uporabe |
| EP2914591B1 (en) | 2012-11-03 | 2017-10-11 | Boehringer Ingelheim International GmbH | Inhibitors of cytomegalovirus |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US20150336960A1 (en) | 2012-12-19 | 2015-11-26 | Novartis Ag | Aryl-substituted fused bicyclic pyridazine compounds |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| ES2656012T3 (es) | 2013-02-06 | 2018-02-22 | Bayer Cropscience Aktiengesellschaft | Derivados de pirazol sustituidos con halógeno como pesticidas |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| MX2016004946A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Procesos para la preparacion de compuestos plaguicidas. |
| JP2016536296A (ja) | 2013-10-17 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
| KR20160075565A (ko) | 2013-10-17 | 2016-06-29 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
| WO2015058024A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| WO2015058028A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| EP3057431A4 (en) | 2013-10-17 | 2017-04-05 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
| CA2925873A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9282740B2 (en) | 2013-10-22 | 2016-03-15 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| MX2016005306A (es) | 2013-10-22 | 2016-08-12 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
| RU2016119576A (ru) | 2013-10-22 | 2017-11-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергетические пестицидные композиции и связанные с ними способы |
| CN105658064A (zh) | 2013-10-22 | 2016-06-08 | 美国陶氏益农公司 | 协同杀虫组合物和相关方法 |
| RU2016119560A (ru) | 2013-10-22 | 2017-11-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергетические пестицидные композиции и относящиеся к ним способы |
| AR098092A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas sinérgicas y los métodos relacionados |
| MX2016005317A (es) | 2013-10-22 | 2016-08-12 | Dow Agrosciences Llc | Composiciones pesticidas y metodos relacionados. |
| RU2656391C2 (ru) | 2013-10-22 | 2018-06-05 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Пестицидные композиции и связанные с ними способы |
| KR20160074634A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 상승작용적 살충 조성물 및 관련 방법 |
| TW201519786A (zh) | 2013-10-22 | 2015-06-01 | 陶氏農業科學公司 | 殺蟲組成物及相關方法（一） |
| MX2016005304A (es) | 2013-10-22 | 2017-03-01 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
| KR20160074640A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 살충 조성물 및 관련 방법 |
| US9137998B2 (en) | 2013-10-22 | 2015-09-22 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| JP2016535733A (ja) | 2013-10-22 | 2016-11-17 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
| JP2016536307A (ja) | 2013-10-22 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | 農薬組成物および関連する方法 |
| AR098099A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas sinérgicas y los métodos relacionados |
| RU2016119368A (ru) | 2013-10-22 | 2017-11-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергетические пестицидные композиции и связанные с ними способы |
| TW201609651A (zh) * | 2013-11-12 | 2016-03-16 | 陶氏農業科學公司 | 用於氟化化合物之過程（一） |
| CA2939848A1 (en) | 2014-03-18 | 2015-09-24 | F. Hoffmann-La Roche Ag | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9029555B1 (en) | 2014-07-31 | 2015-05-12 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| CN106470976A (zh) | 2014-07-31 | 2017-03-01 | 美国陶氏益农公司 | 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法 |
| AR098110A1 (es) | 2014-07-31 | 2016-05-04 | Dow Agrosciences Llc | Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina |
| BR112017002735A2 (pt) | 2014-08-19 | 2017-12-19 | Dow Agrosciences Llc | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina |
| KR20170058388A (ko) | 2014-09-12 | 2017-05-26 | 다우 아그로사이언시즈 엘엘씨 | 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| ES2899906T3 (es) | 2015-07-06 | 2022-03-15 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2018098413A1 (en) * | 2016-11-28 | 2018-05-31 | Bristol-Myers Squibb Company | Pyrimidine carboxamides as gsk-3 inhibitors |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2018125817A1 (en) | 2016-12-29 | 2018-07-05 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| CN110139853B (zh) | 2016-12-29 | 2023-06-16 | 美国陶氏益农公司 | 用于制备杀有害生物化合物的方法 |
| ES2875562T3 (es) | 2017-01-11 | 2021-11-10 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| EP3773560A4 (en) | 2018-04-13 | 2022-01-19 | Sumitomo Dainippon Pharma Oncology, Inc. | PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| CA3135740A1 (en) * | 2018-05-04 | 2019-11-07 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20220289679A1 (en) * | 2019-07-29 | 2022-09-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2023372386A1 (en) | 2022-10-31 | 2025-05-08 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
| EP4626878A1 (en) | 2022-12-02 | 2025-10-08 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| WO2008054749A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| WO2008054701A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
| WO2009058728A1 (en) * | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
| CN101679266A (zh) * | 2007-03-01 | 2010-03-24 | 诺瓦提斯公司 | Pim激酶抑制剂及其应用方法 |
| WO2011029802A1 (en) * | 2009-09-08 | 2011-03-17 | F. Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223526A (en) * | 1991-12-06 | 1993-06-29 | Monsanto Company | Pyrazole carboxanilide fungicides and use |
| GB0412072D0 (en) * | 2004-05-28 | 2004-06-30 | Syngenta Participations Ag | Chemical compounds |
| CN101426774B (zh) * | 2006-04-19 | 2012-04-25 | 安斯泰来制药有限公司 | 唑类甲酰胺衍生物 |
| JP5349309B2 (ja) * | 2007-08-03 | 2013-11-20 | 株式会社キノファーマ | 抗ｄｎａウイルス作用を有するアニリン誘導体 |
| AR070531A1 (es) * | 2008-03-03 | 2010-04-14 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
| BRPI0918268B1 (pt) * | 2008-09-02 | 2021-08-03 | Novartis Ag | Derivados de picolinamida, seu uso, e composição farmacêutica |
-
2011
- 2011-07-04 WO PCT/EP2011/061198 patent/WO2012004217A1/en not_active Ceased
- 2011-07-04 JP JP2013517331A patent/JP2013530199A/ja active Pending
- 2011-07-04 CN CN2011800335423A patent/CN103080106A/zh active Pending
- 2011-07-04 EP EP11729624.4A patent/EP2590968A1/en not_active Withdrawn
- 2011-07-04 US US13/807,993 patent/US20130109682A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| WO2008054749A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| WO2008054701A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| CN101679266A (zh) * | 2007-03-01 | 2010-03-24 | 诺瓦提斯公司 | Pim激酶抑制剂及其应用方法 |
| WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
| WO2009058728A1 (en) * | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
| WO2011029802A1 (en) * | 2009-09-08 | 2011-03-17 | F. Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| TERENCE A. KELLY，等: ""Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. 5. 4-Substituted and 2,4-Disubstituted Analogs of Nevirapine"", 《J. MED. CHEM.》 * |
| UPENDER VELAPARTHI，等: ""Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)"", 《BIOORG. MED. CHEM. LETT.》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795151A (zh) * | 2014-08-06 | 2017-05-31 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| US10508101B2 (en) | 2014-08-06 | 2019-12-17 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| CN106795151B (zh) * | 2014-08-06 | 2021-05-07 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| US11059804B2 (en) | 2014-08-06 | 2021-07-13 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| US11505541B2 (en) | 2014-08-06 | 2022-11-22 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| CN110713476A (zh) * | 2019-11-07 | 2020-01-21 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-甲基-4h-吡喃-4-酮的合成方法 |
| CN110790737A (zh) * | 2019-11-07 | 2020-02-14 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
| CN110790737B (zh) * | 2019-11-07 | 2022-07-22 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
| CN110713476B (zh) * | 2019-11-07 | 2022-07-26 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-甲基-4h-吡喃-4-酮的合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013530199A (ja) | 2013-07-25 |
| US20130109682A1 (en) | 2013-05-02 |
| EP2590968A1 (en) | 2013-05-15 |
| WO2012004217A1 (en) | 2012-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103080106A (zh) | 用作激酶抑制剂的环醚化合物 | |
| CN102203079B (zh) | 作为激酶抑制剂的吡啶甲酰胺衍生物 | |
| CN102015701B (zh) | Pim激酶抑制剂及其应用方法 | |
| JP5564045B2 (ja) | 二環式キナーゼ阻害剤 | |
| JP6204462B2 (ja) | キナーゼ阻害剤としての新規環置換ｎ−ピリジニルアミド | |
| CN103402984A (zh) | 新的激酶抑制剂 | |
| TW202523663A (zh) | KRas G12D抑制劑 | |
| CN119241481A (zh) | 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物 | |
| KR102339227B1 (ko) | Gsk-3 억제제 | |
| CN103429572A (zh) | 作为激酶抑制剂的四取代的环己基化合物 | |
| KR20150058257A (ko) | 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법 | |
| CN114144230A (zh) | 作为eed和prc2调节剂的大环唑并吡啶衍生物 | |
| CN119119033A (zh) | 吡唑并吡啶酮化合物 | |
| CN120957998A (zh) | 作为MTA-协同PRMT5抑制剂的5-氨基-6,8-二氢-1H-呋喃并[3,4-d]吡咯并[3,2-b]吡啶-2-甲酰胺衍生物 | |
| EP3524602A1 (en) | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | |
| CN120731203A (zh) | 作为mettl3抑制剂的哌啶衍生物 | |
| HK40010063A (en) | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | |
| HK1162022B (en) | Picolinamide derivatives as kinase inhibitors | |
| HK1210155B (zh) | 含氮杂环化合物或其盐 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Address before: Basel Applicant before: Novartis AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130501 |